Ipsen SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ipsen SA Announces Positive Results from Phase III CLARINET Study of Somatuline Autogel 120mg in Gastrointestinal and Pancreatic Neuroendocrine Tumors
Ipsen SA announced results from the primary endpoint of the CLARINET study, assessing the effect of Somatuline Autogel 120 mg on tumor progression-free survival in patients with GEP-NETs. Treatment with Somatuline Autogel 120mg was found to be statistically significantly superior to placebo in extending time to either disease progression or death. The safety profile observed in the study is consistent with the known safety profile of Somatuline.
Latest Developments for Ipsen SA
- Ipsen SA announces new drug application submitted to U.S. Food And Drug Administration
- Ipsen SA announces first set of results on positive phase III clinical study of Dysport in treatment of adults suffering from Upper Limb Spasticity
- Ipsen SA announces positive results from phase IIa clinical study of Dysport in treatment of patients with Neurogenic Detrusor Overactivity (NDO)
- Ipsen SA announces positive top line results from phase III clinical study of Decapeptyl
Latest Key Developments in Pharmaceuticals
- Share this
- Digg this